Keeley Phelps
Payments from drug & device makers
Across 104 payments — averaging $16.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$420
- Lilly USA, LLC$254
- AstraZeneca$190
- AbbVie$163
- Pfizer$98
- Novartis$80
- plus $472 from 11 others
What the payments were for
- Food & beverage$1,677100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $420 |
| Lilly USA, LLC | 16 | $254 |
| AstraZeneca | 11 | $190 |
| AbbVie | 9 | $163 |
| Pfizer | 6 | $98 |
| Novartis | 4 | $80 |
| E.r. Squibb & Sons, L.L.C. | 5 | $73 |
| Exact Sciences | 3 | $63 |
| Nestle Healthcare Nutrition Inc. | 4 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| GSK | 3 | $45 |
| Indivior Inc. | 2 | $45 |
| Merck | 2 | $38 |
| Amgen | 2 | $32 |
| Bayer | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
How this compares
$1,677 in reported general payments places this provider in the 80th percentile of 4,717 family providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 69 | $94,972 |
| EliquisApixaban | 86 | $67,800 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $37,800 |
| JardianceEmpagliflozin | 40 | $34,270 |
| TradjentaLinagliptin | 21 | $25,690 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $24,663 |
| JanuviaSitagliptin Phosphate | 13 | $19,089 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 43 | $16,771 |
| XareltoRivaroxaban | 15 | $16,387 |
| FarxigaDapagliflozin Propanediol | 18 | $12,486 |
| LinzessLinaclotide | 14 | $8,142 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $7,100 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $6,228 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $2,706 |
| Pantoprazole Sodium | 178 | $2,431 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $420 | $94,97269 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $45 | $69,56398 claims |
| PfizerEliquis | $98 | $67,80086 claims |
| MerckJanuvia | $38 | $19,08913 claims |
| Johnson & JohnsonXarelto | $14 | $16,38715 claims |
| AstraZenecaFarxiga | $190 | $12,48618 claims |
| AbbVieLinzess, Synthroid | $163 | $10,29653 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,717 family providers in Pennsylvania.
Other family in Corry
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.